南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.
Investing.com -- Alector Inc.宣布,其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响,该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示,由于试验未能达到主要终点,将终止AL002的长期延伸研究。针对这一发展,Alector还透露计划裁减约17%的员工。
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.
Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.
Alector, Inc. has a 1-year low of $3.69 and a 1-year high of $8.90. The stock has a market capitalization of $368.22 million, a price-to-earnings ratio of -2.19 and a beta of 0.66.
Alector是一家专注于开发针对神经变性疾病治疗方案的生物制药公司。根据最近发布的财报,公司在第三季度实现营业收入1534万美元,但净利润为负,亏损达到4222万美元,每股亏损0.43美元。从市盈率来看,其为负3.08倍,显示出公司当前的财务状况远未达到盈利的水平。这种盈利能力的缺失无疑是今天股价下跌的一个重要原因。
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company ...
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...
Alector ( (ALEC) ) has released its Q3 earnings. Here is a breakdown of the information Alector presented to its investors.Don't Miss our Black ...
北京时间2024年11月14日03时45分,Alector, Inc.(ALEC.us)股票出现异动,股价大幅跳水5.23%。截至发稿,该股报5.26美元/股,成交量24.2581万股, 换手率 0.25%,振幅7.57%。